Analytical Data
-
Gene name
ibpA
- Application
-
Alternative Names
16 kDa heat shock protein A
-
Species
Yersinia pestis bv. Antiqua
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q1CD74
-
Expression Region
1-137aa
-
Molecular Weight
21.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of IBP A (Inhibitor of apoptosis protein B) recombinant proteins has garnered significant interest in the fields of molecular biology and therapeutic development due to their essential role in regulating apoptosis, a critical process for maintaining cellular homeostasis and development. Apoptosis dysregulation is linked to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases, making the understanding of apoptotic pathways crucial for designing targeted therapies. IBP A proteins are known to inhibit caspases, the key effectors in the apoptotic pathway, thus preventing programmed cell death. Research into recombinant IBP A proteins involves the expression and purification of these proteins for structural and functional studies. Such studies aim to elucidate the molecular mechanisms by which IBP A modulates apoptosis and the potential for therapeutic applications. Furthermore, the exploration of IBP A's interactions with other apoptotic regulators can provide insights into novel treatment strategies. As recombinant technology advances, the production of IBP A proteins in various host systems paves the way for high-throughput assays and drug discovery processes, highlighting their significance in biotechnology and pharmaceutical research. The ongoing investigation aims not only to understand the fundamental biology of IBP A but also to leverage its properties in the development of innovative therapies for apoptosis-related diseases.
